合生元益生菌治疗自发性高血压相关机制的代谢组学研究

目的 应用代谢组学相关技术，从表观水平探索合生元制剂通过调节肠道菌群达到降压效应的可能作用机制。方法 将14只自发性高血压大鼠随机分为2组，模型组和治疗组各7只，另取7只Wistar Kyoto大鼠作为对照组，采用超高效液相色谱-四级杆飞行时间串联质谱（UHPLC-Q-TOF/MS）技术对对照组、原发性高血压模型组和合生元制剂治疗组的大鼠模型回肠段进行代谢组学分析，筛选合生元制剂治疗自发性高血压的潜在生物学标志物。结果 通过对代谢组学的分析，确定了对照组与模型组之间具有显著差异的27种代谢物。在这些代谢物中，与模型组相比，治疗组中溶血磷脂酰乙醇胺（LysoPE）和磷脂酰胆碱（PC）可以显著被重新调节。结论 合生元制剂可以通过改变肠道微生物群的结构，调节LysoPE和PC相关信号通路，进而改善自发性高血压状态；代谢组学有助于从分子水平理解自发性高血压发病机制及合生元制剂的降压机制。

Metabonomics study on the antihypertensive mechanism of lactobacillus and bifidobacterium in the spontaneous hypertensive rats

Objective To explore the possible mechanism of synergistic effect of synbiotic preparations by regulating intestinal flora to achieve antihypertensive effect by the metabolomics-related techniques.Methods Fourteen spontaneously hypertensive rats were randomly divided into two groups,7 rats in each of the model group and the treatment group,and another 7 Wistar Kyoto rats were used as the control group.Ileum metabolic profiling among the control group,Spontaneous hypertension model group and symbiotic treatment group were analyzed by ultra-high performance liquid chromatography coupled with tandem quadrupole time of flight mass spectrometry (UHPLC-Q-TOF MS).The potential biomarkers for the treatment of spontaneous hypertension were selected.Results In additional,27 metabolites with significant differences between the control and model group were identified by analysis of metabonomics.Among these metabolites,LysoPE and PC could be significantly re-regulated in the treatment group,compared with the model group.Conclusion Synbiotics could improve the status of spontaneous hypertension by changing the structure of the intestinal microbiota,regulating LysoPE and PC-related signaling pathways.Metabolomics could help to understand the pathogenesis of essential hypertension and the hypotensive mechanism of synbiotics at the molecular level.